Results 71 to 80 of about 9,855 (176)

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

open access: yesAngewandte Chemie International Edition, Volume 65, Issue 39, 21 September 2026.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber   +4 more
wiley   +1 more source

Candida auris

open access: yesJournal of Immunology, Allergy and Infection in Otorhinolaryngology, 2022
Hirose, Yuki, Tabuchi, Keiji
openaire   +2 more sources

Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry

open access: yesJournal of Fungi, 2019
Candida auris has emerged globally as a multidrug-resistant fungal pathogen. Isolates of C. auris are reported to be misidentified as Candida haemulonii. The aim of the study was to compare the heat production profiles of C.
Mariagrazia Di Luca   +5 more
doaj   +1 more source

Opportunistic Infections due to Candida auris in Patients with Multiple Comorbidities

open access: yesJK Science
The Candida species are usually considered as commensals on skin, mucous membrane, and gastrointestinal tract. Among various non-albicans Candida species, Candida auris is gaining importance due to serious outbreaks of invasive infections in healthcare ...
Peetam Singh   +2 more
doaj  

Candida auris [PDF]

open access: yesCanadian Medical Association Journal, 2019
Ilan S, Schwartz, Tanis C, Dingle
openaire   +2 more sources

Candida auris: A Continuing Threat

open access: yesMicroorganisms
Candida auris is a World Health Organization critical-priority fungal pathogen that has variable resistance to antifungal treatments. Multiple clades have been identified through genomic analysis and have appeared in different geographic locations simultaneously.
Ashish Bhargava   +4 more
openaire   +3 more sources

FIRST CASES IN BULGARIA WITH PROVEN CANDIDA AURIS IN IMMUNOCOMPROMISED PATIENTS

open access: yesProblems of Infectious and Parasitic Diseases
Candida auris is a fungus with pathogenic potential, first isolated in 2009 in Japan. Since then, sporadic cases have been reported, which have increased significantly in recent years.
Lyubomira Boyanova   +2 more
doaj   +1 more source

Candida auris

open access: yesNursing
Abstract: Candida auris (C. auris) is a human pathogen that can colonize the skin and various body sites without signs or symptoms or cause serious invasive infections with high mortality. The number of cases involving drug-resistant C. auris infections have increased in the US in recent years.
Jenks JD, Tobin EH, Zahra F.
europepmc   +5 more sources

First prospectively identified case of Candida auris in the United States

open access: yesOtolaryngology Case Reports, 2017
Candida auris is an emerging multidrug-resistant fungus associated with high mortality rates. With a predilection for immunocompromised patients, C. auris has been reported to be the cause of several nosocomial outbreaks. Conventional biochemical methods
Anthony Yang   +4 more
doaj   +1 more source

Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack

open access: yesmBio, 2018
Candida auris has recently emerged as the first fungal pathogen to cause a global public health threat. The reason this species is causing hospital-associated outbreaks of invasive candidiasis with high mortality is unknown. In this study, we examine the
Chad J. Johnson   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy